Some warning signs need care before a sales visit

Sudden changes need medical attention

A joint that's both hot and swollen, especially with fever, needs prompt medical help. Sudden trouble bearing weight or new numbness and weakness also needs quick care.

A new sore, swollen calf after any procedure can mean a clot. Fever or redness that keeps spreading afterward may signal infection.

Severe wear may need another opinion

A joint that's badly bent, sore at rest, or hard to use deserves a surgical opinion. Paying for repeated procedures may only delay care that fits better.

Ask what the exam and X-ray show before choosing. If the answer isn't clear, take the written plan to another doctor.

Bring an older X-ray if one is available. Don't discuss payment until someone explains whether the wear has worsened.

Some people need different care first

QC Kinetix provides regenerative treatment options, office procedures that may use prepared blood, bone marrow, or fat. This care may be wrong during an infection, with an untreated bleeding problem, or during active cancer care.

Tell the doctor if you take a blood thinner, since it can raise bleeding risk during a procedure. Other medicines may matter, so let the doctor who prescribed them guide any change.

Active cancer care also needs a decision from the doctor managing it. Don't stop medicine or delay cancer care for a joint visit.

Pressure is a reason to wait

It's fine to leave the first visit without choosing. Take the price, visit schedule, and proposed care home with you.

Ask what relief is realistic and whether waiting changes your choices. Pressure to decide is a good reason to leave and get another doctor's view.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

3. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.